Company Analysis
Sign in

Neuphoria Therapeutics Inc. (NEUP)

Nasdaq: NEUP · Pharmaceutical Preparations · Burlington, MA · filing with the SEC since 2002
Full chart Alerts Compare
Grade4.5
◀ Past 3.5● Present 4.4▶ Future 5.1
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Neuphoria Therapeutics Inc.

Nine metrics read from its own filings, by tense
Headline grade
4.5/10
◀ Past3.525% of the headline
● Present4.435% of the headline
▶ Future5.140% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 4 read as filed from the record and 5 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.5/1025% of the headline grade · 1 of 3 filed, 2 estimated

Surviving crises

as filed
2.1/10

Has it survived what it has been through?

6 warning events since 2017; the latest 2025-12-18.

weight 22% of this tense · 21st percentile among 497 sector filers · read for itself

From the record

Neuphoria Therapeutics Inc.'s filings since 2017 show 6 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 5 times, the latest 2025-12-18); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2025-05-15) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

SI estimate
5.1/10

What has it actually done, year after year?

SI estimate 5.1/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 324 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate
Fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 324 members with one.
What the record cannot read
Fewer than three filed years of revenue on file.
How it was reasoned
family median, 324 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Neuphoria Therapeutics Inc.'s track record is put at 5.1 of 10 with a confidence of 20 of 100, because fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 324 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Shareholder treatment

SI estimate
2.3/10

How has it treated the people who own it?

SI estimate 2.3/10, confidence 35 of 100 (one part).

weight 33% of this tense · 23rd percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 23% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Neuphoria Therapeutics Inc.'s shareholder treatment is put at 2.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 23% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.4/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
4.8/10

Is it financially healthy right now?

ROE -55%: lost 55¢ per shareholder dollar. Leverage 14%: owes 14¢ per asset dollar.

weight 45% of this tense · 48th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2026-06-30, Neuphoria Therapeutics Inc. lost about 55 cents for every dollar of shareholders' money. Leverage: it owed about 14 cents per dollar of assets, and net share issuance: its share count grew 170.9% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 24% of its family
  • return on equitybottom 49% of its family
  • the share count against the year beforebottom 19% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
1.8/10

How strong is its position in its industry?

bottom 17% of 315 in its family; net margin -1145.7%.

weight 22% of this tense · 17th percentile among 315 sector filers · read for its customers

From the record

Neuphoria Therapeutics Inc.'s standing among 315 graded names in its industry family: revenue of $1 million in fiscal 2026 ranks in the bottom 24% by size; a net margin of -1145.7% ranks in the bottom 28%; revenue growth of -92.5% a year over the last 1 filed years ranks in the bottom 1% (its annual reports).

What it rests on

  • revenue against the family$1.2Mbottom 24% of its family
  • net margin-1145.7%bottom 28% of its family
  • three-year revenue growth-92.5%bottom 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
5.8/10

What are the people in charge doing?

SI estimate 5.8/10, confidence 35 of 100 (one part).

weight 33% of this tense · 58th percentile among 415 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 42% of 415 in its family; the record of its people begins on 2024-07-08 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.3 years and cannot see past it; a floor under five years is not read as years in charge.
What the record cannot read
The record of its people begins on 2024-07-08 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.3 years and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned
one part: officer and director changes on Form 8-K, against the people in charge, the one part on file, ranked among 415 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Neuphoria Therapeutics Inc.'s leadership is put at 5.8 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 42% of 415 in its family; the record of its people begins on 2024-07-08 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.3 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

5.1/1040% of the headline grade · 1 of 3 filed, 2 estimated

Room to expand

as filed
5.0/10

How much room does it have to grow?

top 49% of 273 in its family for room to expand.

weight 33% of this tense · 51st percentile among 273 sector filers · read for itself

From the record

Neuphoria Therapeutics Inc.'s room to grow, from the newest filed statements (fiscal 2026): cash of $20 million against no long-term debt tagged leaves 69.2% of its assets as net cash, top 23% of its family; cash from operations less capital spending is -1052.1% of revenue (bottom 24%) (its annual report).

What it rests on

  • cash less debt against assets69.2%top 23% of its family
  • cash from operations less capital spending against revenue-1052.1%bottom 24% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

SI estimate
5.0/10

What could actually drive growth from here?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 307 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate
The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 307 members with one.
What the record cannot read
The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending.
How it was reasoned
family median, 307 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Neuphoria Therapeutics Inc.'s growth drivers is put at 5.0 of 10 with a confidence of 20 of 100, because the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 307 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Expectations vs reality

SI estimate
5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
family median, 234 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Neuphoria Therapeutics Inc.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton NEUP · research, not advice